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Abstract Clq receptor (ClqRkoIIectin receptor) is located on 
many ceII types. Binding of Clq to these cells elicits numerous 
responses. Protein sequencing has shown that ClqR is almost 
identical to cabetictdin (CaR), an abundant multifunctional 
protein. Radioiodinated ClqR and CaR bind to Clq with 
identical characteristics. Three recombinant ClqR/CaR domains 
(N-, C-terminal domains and central P-domain) were expressed 
using the Thiofusion system, and used to study the interaction 
with Clq. Both the N- and P-domains were implicated in Clq 
binding. A region, termed the S-domain, spanning the N and P 
intersection was expressed, and showed concentration-dependent 
binding to Clq, demonstrating that the Clq binding site lies 
within this region. 
Key words: Clq receptor; Calreticulin; Clq binding site; 
Collagen; Complement 
1. Introduction 
A cell surface receptor which binds to the collagenous re- 
gion of Clq, the recognition subunit of the first component of 
complement, has previously been isolated [l]. Protein sequenc- 
ing studies of this molecule, the Clq receptor (ClqR or col- 
lectin receptor), have shown [l] that it is almost identical to 
calreticulin (CaR), a highly conserved abundant calcium-bind- 
ing protein that was initially identified in skeletal muscle sar- 
coplasmic reticulum [2]. ClqR and CaR are both 47-kDa 
proteins (from mass spectroscopy [3]) with an apparent mo- 
lecular weight of 56 kDa on SDS-PAGE. Immunohistochem- 
ical studies have shown that ClqR is located on the surface of 
leukocytes, endothelial cells, fibroblasts, platelets and special- 
ised epithelia [4]. Binding of Clq to ClqR on these cell types 
elicits a range of immunological responses, such as phagocy- 
tosis, enhanced cytokine and antibody production and anti- 
body-dependent cell cytotoxicity [5,6]. ClqR also binds to the 
collectin proteins SP-A, MBL, CL43 and conglutinin [7,8]. 
The mode of attachment of ClqR/cell surface CaR to the 
plasma membrane remains uncertain. 
A number of proteins with identical or highly homologous 
sequence to CaR have recently been identified in different 
cellular compartments, indicating that CaR has a highly di- 
verse functional repertoire [9]. At present, over 40 functions 
have been described for CaR; however, the number of signif- 
icant roles in vivo is likely to be much lower. CaR or CaR-like 
molecules have been suggested to act as: a heat shock/stress 
protein [lo], chaperone [ 11,121, steroid hormone receptor 
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[13,14], Mg2+ or Zn2+ binding protein [15,16] and PDI bind- 
ing protein [17]. CaR also affects replication of rubella virus 
RNA [18] and intracellular Ca2+ homeostasis [19-211. CaR 
may also participate in the normal immune response and in 
autoimmunity [22]. Cell surface CaR may trigger cell spread- 
ing [23]. CaR, like ClqR, binds to Clq and the collectins [24]. 
The interaction between ClqR and Clq is ionic strength- 
dependent [25], and involves a region of charged residues on 
the collagen stalks of the Clq ligand [26]. However the region 
within ClqR that binds to the ligand has yet to be elucidated. 
Despite the minor reported sequence differences between 
ClqR and CaR (Fig. 1) we show that the two proteins inter- 
act in an identical fashion with Clq and collagens, indicating 
that there is a common Clq binding region within ClqR and 
CaR. Due to the high degree of similarity between CaR and 
ClqR, the protein will be referred to as ClqR/CaR. 
A cDNA clone (phCaR-1) was isolated from a human um- 
bilical vein endothelial cell cDNA library cloned in the expres- 
sion vector CDM8. The coding sequence of phCaR-1 was 
identical to the previously published CaR sequence [27]. Clone 
phCaR-1 was used to produce recombinant protein segments 
to be tested for Clq binding function. These N-, P- and C- 
domains, as described below, have previously been used to 
localise CaR function within the molecule [28]. The amino- 
terminal N-domain contains the binding regions for PDI [17], 
Zn2+ [29] and a-integrins [23]. The proline-rich central P-do- 
main contains the high affinity Ca2+ binding site [30]. The 
acidic C-domain contains the ER-retention terminal KDEL 
signal [27]. This domain also contains a putative glycosylation 
site and the low affinity Ca ‘+ binding site [30]. Our studies 
have localised the Clq binding site across the intersection of 
the N- and P-domains. Within this region we identified and 
expressed a subfragment (the S-domain) and showed that it 
represents the Clq binding site of ClqR/CaR. 
2. Materials and methods 
2.1. PuriJication and radioiodination of native ClqR and native 
calreticulin 
Native ClqR was purified from human U937 cells as previously 
described [I]. Briefly, U937 cells were lysed in 10 mM sodium phos- 
phate, 2 mM EDTA (pH 7.4) containing non-ionic detergent, fol- 
lowed by chromatography on DEAE-Sephacel, FPLC mono-Q ion 
exchange and FPLC Superose-6 gel filtration (Pharmacia, St. Albans, 
Herts., UK). ClqR fractions were further purified on a TSK-gel 
DEAE-NPR high performance liquid chromatography column. Pure 
ClqR fractions were stored in 10 mM sodium phosphate, 2 mM 
EDTA (pH 7.4) at -20°C. Native ClqR was also purified from hu- 
man tonsil lymphocytes (obtained from the E.N.T. Department, Rad- 
cliffe Infirmary, Oxford) by the same method. 
Native CaR was purified from human tonsils as previously de- 
scribed [31] with modifications. Briefly, 100 g human tonsils were 
homogenised and CaR precipitated with 85% saturation of ammo- 
nium sulphate (pH 4.0). Redissolved protein was fractionated on a 
high-load Q-Sepharose column (Pharmacia) and then. as for ClqR, 
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further purified by FPLC Superose-6 gel filtration and TSK gel 
DEAE-NPR HPLC. Pure CaR fractions were stored in 10 mM so- 
dium phosphate, 2 mM EDTA (pH 7.4) at -20°C. 
Native ClqR and CaR samples (25 pg in 10 mM sodium phosphate 
buffer, 2 mM EDTA (pH 7.4)) were iodinated with iz51 by the Iodo- 
gen method [32]. Radiolabelled fractions were stored at 4°C. 
2.2. PuriJication and radioiodination of Clq 
Clq was purified as previously described [33] and radioiodinated 
(40 ug, in 100 mM sodium borate (pH 8.5)) by the method of Bolton 
and Hunter [34]. This method of iodination causes less damage to 
large, oxidation-sensitive molecules such as Clq than the Iodogen 
method [35,36]. Radiolabelled fractions were pooled and stored in 
10 mM potassium phosphate, 0.25% (w/v) gelatin at 4°C. 
Soluble collagens (in 0.1 M acetic acid) were a generous gift from 
Prof. R. Timpl, Max-Planck-Institut fur Biochemie, Martinsried, Ger- 
many. Acid-soluble type I collagen was purified from calf skin; pep- 
sin-solubilized collagens type III, V and VI were purified from human 
placenta; bacterial collagenase-solubilized type IV collagen was pre- 
pared from EHS tumour cells. 
2.3. Binding of native ClqR and native CaR to collagens and Clq 
The solubilized collagens were neutralized to pH 7.0 with NaOH. 
Microtitre plates were coated with the collagens, Clq or BSA (100 ~1: 
10 &ml in 35 mM NaHCOa, 15 mM NasCOs pH 9.6) for 2 h at 
37°C. After washing with 10 mM potassium phosphate, 0.5 mM 
EDTA pH 7.4, non-specific interactions were blocked by incubation 
with the same buffer containing BSA (10 mg/ml). Radiolabelled native 
ClqR or native CaR samples (2X lo5 cpm per well), in 10 mM po- 
tassium phosphate (pH 7.4) containing different concentrations of 
NaCl, were added to the wells and incubated overnight at 4°C. Wells 
were washed three times with the phosphate buffer and bound radio- 
activity eluted with 200 ml 4 M NaOH per well. 
2.4. Prokaryotic expression of recombinant Clq receptorlcalreticulin 
domains 
A 1.9-kb cDNA clone for CaR (phCaR-1) was isolated from a 
human umbilical vein endothelial cell library (kindly donated by Dr 
B. Seed, M.I.T., Boston, MA, USA) in the eukaryotic expression 
vector CDMS [37]. Sequence analysis revealed that phCaR-1 com- 
prised the complete coding sequence for CaR with absolute identity 
to the previously published CaR sequence [27]. The Thiobond expres- 
sion system was used to produce N-, P-, C- and S-domains of ClqR/ 
CaR (representing the N-terminal region, the proline-rich central re- 
gion, the C-terminal region, and a region spanning the intersection of 
the N- and P-domains (Table 1)). The individual recombinant do- 
mains of human ClqR/CaR were expressed as thioredoxin fusion 
proteins in E. coli using the plasmid pTrxfus (Invitrogen BV, Leek, 
The Netherlands). 
Oligonucleotide primer pairs were generated for each recombinant 
ClqR/CaR domain. Sense and antisense primers were modified to 
include sites for XbaI and SalI digests, respectively. Clone phCaR-1 
was used as a template for PCR. PCR amplification products were 
ligated into pCRI1 (Invitrogen). Plasmid DNA was prepared, double 
digested with XbaIlSalI and separated on an agarose gel. ClqR/CaR 
cDNA fragments were cut from the gel, extracted using the Sephaglas 
Bandprep kit (Pharmacia), and ligated into pTrxfus that had been 
linearised with SalI and XbaI. The constructs were transformed into 
E. coli strain G1724 and plasmid DNA isolated and sequenced. 
Single colonies carrying each construct were inoculated into RMG- 
Amp medium (1 XM9 salts, 2% casamino acids, 0.5% glucose, 1 mM 
MgCla and 100 @/ml ampicillin) and grown overnight at 30°C. In- 
duction medium (RMG-Amp) was inoculated with the cultures and 
incubated at 30°C until ODsss reached -0.5. L-Tryptophan (100 l.~Lpl 
ml) was added to induce protein expression and the cells grown for 4 h 
at 37°C before harvesting. Cells expressing the N-domain were resus- 
pended in TSB (200 mM NaCl, 100 mM Tris-HCl. 1 mM EDTA DH 
7.0). 0.1 mM PMSF, and lysed by three cycles of sonication, rapid 
freezing and thawing. Following centrifugation, the clear supernatant 
(8 mg/ml of protein) was bound to Thiobond resin (Invitrogen) and 
purified protein eluted with TSB, 2-mercaptoethanol (5-500 mM). 
The recombinant P-, C- and S-domains were purified after osmotic 
shock as the thioredoxin fusion partner localises protein in an osmo- 
tically sensitive compartment between the cell wall and plasma mem- 
brane in E. coli. [38]. Samples were assayed for recombinant ClqRI 
ClqR peptide CaR sequence similarity 
YKGRQT Two KG-QT sequences 
KPADMS-S KPEDWDKP (residues 232-239) 
Fig. 1. Reported sequence differences between Clq receptor and cal- 
reticulin. ClqR proteolysis fragment peptides sequences [l], not 
found in the cDNA-derived amino acid sequence of CaR [27]. A 
third reported sequence difference [l] (DNQSENMS) is now be- 
lieved to be a purification artefact. 
CaR by SDS-PAGE [39] and by Western blotting with rabbit antisera 
to whole native ClqR (raised against human ClqR purified from 
U937 cells [l]), whole native CaR (raised against human CaR purified 
from native tonsils (Section 2. I)), with rabbit antisera with specificity 
for CaR C-terminal region (raised against a GST fusion protein con- 
taining the final 18 residues of human CaR), and for recombinant 
CaR N-terminal region (raised against a GST fusion protein contain- 
ing residues 7718 of recombinant human CaR: kindly donated by Dr 
P. Eggleton, MRC Immunochemistry Unit). The amino acid sequence 
of each expressed recombinant ClqR/CaR domain is shown in Table 
1. 
2.5. Interaction of recombinant CIqRlCaR domains with Clq 
Binding experiments with the recombinant ClqR/CaR domains 
were performed throughout in low salt (10 mM potassium phosphate, 
0.5 mM EDTA (pH 7.4)) in order to maximise the interaction of the 
protein domains with Clq. Fig. 2 demonstrates that the highest levels 
of binding are achieved at low ionic strength. 
2.5.1. Solid phase binding assays. Microtitre plates were coated 
with the recombinant ClqR/CaR domains and with three controls, 
native ClqR (purified as described in Section 2.1) BSA and Thio- 
redoxin, (8 ug/ml in 35 mM NaHCOs, 15 mM NasCOs pH 9.6) for 2 
h at 37°C. Non-specific interactions were blocked as described in 
Section 2.3. Any free -SH groups in the samples, due to the presence 
of the thioredoxin fusion protein, were blocked by a brief washing 
step using phosphate buffer containing 2 mM iodoacetamide. After 
further washing, serial dilutions of radioiodinated Clq (in 10 mM 
potassium phosphate, 0.5 mM EDTA, pH 7.4) were added to the 
wells and incubated overnight at 4°C. Wells were washed three times 
with phosphate buffer and bound radioactivity eluted as described in 
Section 2.3. 
2.5.2. Competitive inhibition of native ClqR-Clq interaction by re- 
combinant ClqRICaR domains. A microtitre plate was coated with 
native ClqR (0.9 pg per well in 35 mM NaHCOs, 15 mM NaaCOs 
pH 9.6). Non-specific binding was blocked by incubation with 10 mM 
potassium phosphate, 0.5 mM EDTA (pH 7.4) containing BSA (10 
mg/ml). Serial dilutions of the recombinant domains, thioredoxin, 
native Cl qR and BSA (maximum quantity = 9 pg/well) were prepared 
in 10 mM potassium phosphate, 0.5 mM EDTA, 2 mM iodoacet- 
amide (pH 7.4). Each dilution (100 ~1) was then incubated for 1 h 
at 37°C with a constant level of radiolabelled Clq and loaded onto 
the plate. Following overnight incubation at 4”C, the wells were 
washed, bound radioactivity eluted using 4 M NaOH and then meas- 
ured. 
2.5.3. Haemolytic assays. The ability of native ClqR and the re- 
combinant ClqR/CaR domains to bind to Clq and interfere with 
binding of ClrsClsz was also determined by haemolysis assays. Sheep 
erythrocytes (E) and rabbit anti-sheep erythrocytes (A) were provided 
by TCS, Botolph Claydon, Oxon, UK. EAClq cells were made as 
previously described [40,41]. Clq deficient serum was obtained from a 
patient with homozygous Clq deficiency. EA and EAClq cells were 
incubated, at 37°C for 1 h, with serial dilutions of Clq-deficient ser- 
um, in order to establish the minimum serum concentration required 
to cause complete lysis of EAClq. EAClq cells (100 pl) were then 
preincubated, at 37°C for 1 h, with native ClqR, or’ recombinant 
ClqR/CaR constructs (100 ul: 100 t&ml). The cells were then incu- 
bated with the appropriate dilution of-Cl&deficient serum at 37°C for 
1 h. The extent of lysis was established by the addition of cold 
DGVB+ i (1 ml), centrifugation, and measurement of the ODdi of 
the supernatant. Controls for 100% lysis comprised 100 ~1 cells and 
1.1 ml water. Initially, fixed concentrations of native ClqR and re- 
combinant ClqR/CaR domains were tested. Based upon this evidence, 
the concentration dependence of inhibitory effects was then tested by 
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Fig. 2. Binding of native Clq receptor and native calreticulin to Clq and collagens. Radioiodinated ClqR or CaR samples were incubated 
with solid phase bound Clq or collagens at varying ionic strength conditions, as described in Section 2.3. 
the use of varying concentrations of native ClqR and recombinant 
ClqR/CaR domains. 
3. Results 
expressed as thioredoxin fusion proteins. Correct expression 
was verified by SDS-PAGE and Western blotting. The do- 
mains were subjected to a number of functional assays, using 
the 12-kDa thioredoxin fusion partner as a negative control. 
3.1. Interaction of native ClqR and CaR with Clq and 
collagens 
Constant concentrations of radioiodinated native ClqR 
and CaR were incubated with Clq or Collagens on a micro- 
titre plate in increasing salt concentrations, as described in 
Section 2.3. Both proteins interact identically, in a salt-de- 
pendent fashion, with Clq, and with collagens III, V, VI 
and, to a lesser extent, collagen I (Fig. 2). Collagen IV showed 
no binding at pH 7.4, but there was low level salt-independent 
binding at pH 5.5 (not shown). Excess soluble collagens 
caused near-complete inhibition of the interaction of Clq 
with radiolabelled ClqR or CaR, indicating that the collagens 
bind via an identical, or an overlapping site, to Clq. (J. Lu, 
unpublished). 
3.2.1. Solid phase binding assays. Fig. 3 summarises the 
results of three separate direct binding experiments. In each 
case, concentration-dependent, saturable binding (not shown) 
of radioiodinated Clq was observed for native ClqR, the P- 
domain and, to a lesser extent, the N-domain. The C-domain 
showed no binding above the BSA background. 
3.2.2. Competitive inhibition of native ClqR-Clq interac- 
tion. The results of competitive inhibition studies are shown 
(Fig. 4). The N-domain and the P-domain show concentra- 
tion-dependent inhibition of binding of radiolabelled Clq to 
immobilised native ClqR. As expected, soluble native ClqR 
also demonstrated inhibition (not shown). Thioredoxin and 
the C-domain had no inhibitory effect, demonstrating that 
they do not bind to Clq. 
3.2. Interaction of recombinant ClqRlCaR domains with Clq 
N-, P-, C- and S-domains of recombinant ClqR/CaR were 
3.2.3. Haemolytic assays - inhibition of Cl assembly and 
activation. Haemolytic assays were also used to investigate 
whether the recombinant domains would disrupt Clq func- 
tion. EAClq cells are mixed with Clq-deficient serum. 
Table 1 
Sequence and position of Clq receptor/calreticulin domain constructs 
Domain Construct seauence 
- 
Kestdues expressed 
N Thioredoxin PLEPAVYF......ESGSLVDL Q 18-196 
S Thioredoxin PLDIRCKD......QIDNPVDLQ 160-283 
P Thioredoxin PLEDDWDF......DPSIYVDLQ 197-306 
C Thioredoxin PLDNFGVL......QAKDEL 3099417 
Constructs were expressed with Thioredoxin fusion products as described in Section 2. The amino acid sequences were deduced from the nucleotide 
sequence of human cDNA [30]. Residues underlined are human ClqRICaR; others are vector or primer derived. 
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Fig. 3. Binding of Clq to recombinant Clq receptor/calreticulin do- 
mains. Recombinant ClqRKaR domains were expressed in E. coli 
and purified as described in Section 2.4. Solid-phase bound do- 
mains, with appropriate controls, were incubated with radioiodi- 
nated Clq. Binding levels obtained in three separate experiments, at 
saturation, were measured and calculated as % (bound/loaded). 
These levels were then standardised against the results for native 
ClqR, taken as 100%. 
Clr&lss in the serum binds to Clq, becomes activated, and 
subsequent activation of the complement system causes cell 
lysis. Species that interfere with the Clq-Clt$lss interaction 
will inhibit lysis. Preliminary results (not shown) using a con- 
stant concentration of recombinant ClqR/CaR domains de- 
monstrated that the P-domain has a stronger inhibitory activ- 
ity than the N-domain. The C-domain did not show 
inhibition. On the basis of these results, a concentration de- 
pendence assay was performed. As shown in Fig. 5, concen- 
tration-dependent inhibition of cell lysis was observed for the 
N- and P-domains. The S-domain, which overlaps parts of the 
N- and P-domain, also clearly shows significant concentra- 
tion-dependent inhibition, demonstrating that it binds to 
o! . - I . ’ - ’ ’ ’ 
0 2 4 6 3 10 
lnhibttory protein (mass excess) 
Fig. 4. Inhibition of the native ClqR-Clq interaction by recombi- 
nant ClqR/CaR domains. Constant levels of radiolabelled Clq, pre- 
incubated with serial dilutions of unlabelled recombinant ClqRI 
CaR domains or Thioredoxin controls, were bound to, and eluted 
from, solid-phase bound native ClqR as described in Section 2.5. 
Clq. The thioredoxin and BSA controls did not show signifi- 
cant inhibition of Cl formation and activation. 
4. Discussion 
Sequence analysis of the 56-kDa surface receptor for Clq, 
MBL, CL43 and SP-A at the protein level revealed a primary 
structure almost identical to calreticulin [l]. Based upon these 
results, we determined and compared the binding character- 
istics of native ClqR and native CaR for aggregated Clq. 
Both ClqR and CaR preparations exhibit identical binding 
profiles, attaining strongest binding activity at low salt 
strength, pointing to the predominantly ionic nature of the 
interaction. Four recombinant subfragments of ClqR/CaR 
were expressed as thioredoxin fusion proteins, three of which 
are subfragments representing previously described CaR do- 
mains. Each single subfragment was recognised by polyclonal 
antisera raised against purified native ClqR, as well as by 
antisera raised against native and recombinant CaR. Several 
recent reports [23,42] describe the presence of CaR on the 
outer surface of cell membranes. These and the results pre- 
sented here provide strong evidence to indicate that ClqR is a 
membrane-associated form of calreticulin. 
In order to localise the Clq binding site within ClqRKaR, 
the different subfragments of recombinant ClqR/CaR were 
assessed in direct and indirect assays for binding to activated 
Clq, using purified native ClqR as a control. The indirect 
binding assay revealed that Clq efficiently binds to the N- 
domain, and to a lesser extent to the P-domain (Fig. 3). Direct 
binding to radiolabelled Clq was demonstrated for the N- 
and P-domains (Fig. 4). No Clq binding activity was ob- 
served for the C-domain. These findings are in agreement 
with the results of a Cl-dependent haemolysis assay, in which 
the fragments were tested for their potential to inhibit com- 
plement activation by binding to Clq (Fig. 5). Here, strong 
inhibitory activity was localised in the S-domain, a subfrag- 
ment which spans the N- and P-domain intersection. These 
60 
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Fig. 5. Inhibition of Cl formation and activation by recombinant 
ClqR/CaR domains. Haemolytic assays were used to test the con- 
centration-dependence of inhibition of Cl formation using varying 
concentrations of recombinant ClqRKaR domains, as described in 
Section 2.5. 
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data indicated that the Clq binding site of ClqR/CaR is 
localised on the S-domain. Site-directed mutagenesis will be 
employed to further refine this Clq binding site. 
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